Press release
Chronic Obstructive Pulmonary Disease Market 2022 Assurance – by Abbott, AstraZeneca, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd, etc
Chronic Obstructive Pulmonary Disease Market
The global chronic obstructive pulmonary disease market has been segmented into medicines, treatments, types, and lastly region. On the basis of medicines, this market has been segmented into antibiotics, bronchodilators, combination inhalers, inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, and theophylline. Antibiotics are useful for fighting bacterial infections. Bronchodilators are medications that open (dilate) the airways (bronchial tubes) of the lung by relaxing bronchial muscles. They allow people with difficulty in breathing to breathe better. A combination inhaler combines two kinds of medicine in one device. Usually, in a combination inhaler, one medicine is corticosteroid while the other is a bronchodilator. Advair Diskus, Breo, Dulera, and Symbicort are some examples of combination inhalers. Some examples of inhaled steroids include Arnuity Ellipta, Flovent, Pulmicort, Qvar, and Symbicort are some examples of inhaled steroids. Oral steroids are the non-narcotic type of powerful prescription medication. Commonly called as a PDE4 inhibitor, phosphodiesterase type 4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4).
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1612
Key Players for Global Chronic Obstructive Pulmonary Disease Market
Market Research Future (MRFR) recognizes the following companies as the key players in Chronic Obstructive Pulmonary Disease Market: There are plenty of large and small market players which operate in this market all over the globe.
The key players in global COPD market are Abbott (USA), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland), GSK (UK), Merck (USA), Novartis AG (Switzerland), and Pfizer Inc (USA).
Latest Industry News
Pulmonx® Corp. has announced that the US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the USA for treating emphysema patients. 30 JUNE 2018
The FDA’s Pulmonary Allergy Drugs Advisory Committee has voted 16-3 against recommending GlaxoSmithKline’s mepolizumab (Nucala) as an add-on treatment to inhaled corticosteroid-based maintenance treatments that claim to reduce flare-ups in patients with COPD. 25 JUL 2018
Regional Analysis for Global Chronic Obstructive Pulmonary Disease Market
The regional segmentation of Global Chronic Obstructive Pulmonary Disease Market covers The Americas (North America & South Americas), Europe, Asia Pacific, and Middle East & Africa (MEA). Among the Americas, North America is the bigger market for COPD, than South America due to advanced medical facilities and more investment in this region, the biggest local markets are the United States of America (USA) and Canada. North America is the largest market among all regional markets.
Due to the reasons same as the Americas, Western Europe is the bigger market, than Eastern Europe. Although the market in whole Europe is decent and steady in Western Europe, the cream of Europe market in France, Germany, Italy, Spain, and the United Kingdom (UK). Europe is the second largest market for COPD.
In the Asia Pacific region, the market is growing due to the high density of population and improving medical facilities in some countries of this region. During the forecast period, Asia Pacific is expected to be the fastest growing market for COPD. The biggest markets in the Asia Pacific are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the MEA region, the market is small due to poor or limited infrastructure and less investment in health care. However, due to hookah smoking, the number of people suffering from COPD is sizable. In this region, the biggest markets are Kuwait, Oman, Saudi Arabia, United Arab Emirates (UAE) and Qatar.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Obstructive Pulmonary Disease Market 2022 Assurance – by Abbott, AstraZeneca, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd, etc here
News-ID: 1330570 • Views: …
More Releases from Market Research Future
Glue Machine Market to Reach USD 14.9 Billion by 2035, Growing at 4.56% CAGR
The Glue Machine Market is witnessing significant growth due to the increasing adoption of adhesive technologies across various industries, including packaging, woodworking, automotive, furniture, and construction. Valued at USD 9.15 billion in 2024, the market is projected to reach USD 14.9 billion by 2035, registering a CAGR of 4.56% between 2025 and 2035.
Glue machines, also known as adhesive application machines, are critical for efficiently dispensing adhesives in industrial and commercial…
Expansion Valves Market to Reach USD 5.39 Billion by 2035, Growing at 4.62% CAGR
The expansion valves market is witnessing steady growth due to increasing demand for efficient heating, ventilation, air conditioning, and refrigeration (HVACR) systems across residential, commercial, and industrial sectors. Valued at USD 3.28 billion in 2024, the market is projected to reach USD 5.39 billion by 2035, growing at a CAGR of 4.62% between 2025 and 2035.
Expansion valves, also known as thermostatic expansion valves (TXVs) or electronic expansion valves (EEVs), are…
Cheese Packaging Market to Reach USD 101.31 Billion by 2034, Growing at 3.50% CA …
The Cheese Packaging Market is poised for steady growth over the next decade due to rising demand for dairy products, evolving consumer preferences, and increasing focus on food safety and sustainability. According to recent estimates, the market was valued at USD 71.87 billion in 2024 and is projected to reach USD 101.31 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.50% between 2025 and 2034.
Cheese packaging…
Maritime Market to Reach USD 2,920 Billion by 2035, Growing at 2.69% CAGR
The Maritime Market is a cornerstone of international trade, logistics, and economic connectivity, serving as the backbone of global commerce. Valued at USD 2,181.1 billion in 2024, the market is projected to expand to USD 2,920 billion by 2035, registering a steady CAGR of 2.69% between 2025 and 2035. Despite modest growth, the industry's scale and importance are unmatched, as more than 80% of global trade volume is carried by…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
